{"id":179012,"name":"ALLIANCE FOR BIOPHARMACEUTICAL COMPETITIVENESS AND INNOVATION","slug":"alliance-for-biopharmaceutical-competitiveness-and-innovation","state":"DC","country":"United States of America","description":"Biopharmaceutical industry","totalSpending":6960000,"filings":33,"yearlySpending":[{"year":2018,"income":570000},{"year":2019,"income":510000},{"year":2020,"income":590000},{"year":2021,"income":800000},{"year":2022,"income":960000},{"year":2023,"income":1010000},{"year":2024,"income":1480000},{"year":2025,"income":1040000}],"issues":["TAX"],"firms":["THE WASHINGTON TAX & PUBLIC POLICY GROUP"],"lobbyists":["GREGORY NICKERSON","JAN FOWLER","BRIAN DIFFELL","KELLI BRIGGS","ZACHARY PRICE","JAMES PEDROTTI"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","Treasury, Dept of","Natl Economic Council (NEC)","Office of Management & Budget (OMB)"],"sampleDescriptions":["Issues related to corporate and international tax reform including issues related to IRC sections 904(d), 951A, 250, 59A, 163(j), 954(c)(6), 172, 174, and 965.  Issues related to Puerto Rico.","Issues related to corporate and international tax reform including issues related to IRC sections 904(d), 951A, 250, 59A, 163(j), 954(c)(6), 172, 174, and 965.  Issues related to Puerto Rico.","Issues related to corporate and international tax reform including issues related to IRC sections 904(d), 951A, 250, 59A, 163(j), 954(c)(6), 172, 174, and 965.  Issues related to Puerto Rico incentive","Issues related to corporate and international tax reform including issues related to IRC sections 904(d), 951A, 250, 59A, 163(j), 954(c)(6), 172, 174, and 965.  Issues related to Puerto Rico incentive","Issues related to corporate and international tax including issues related to IRC sections 904(d), 951A, 250, 59A, 163(j), 954(c)(6), 172, 174, and 965. Issues related to Puerto Rico incentives and ex"],"years":[2018,2019,2020,2021,2022,2023,2024,2025]}